Eversept Partners, LP Prothena Corp Public LTD CO Transaction History

Eversept Partners, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$21.63 - $57.65 $1.48 Million - $3.95 Million	-68,575 Closed	0 $0
Q1 2021 Nov 08, 2023	SELL	$11.0 - $28.24 $1.48 Million - $3.81 Million	-134,753 Reduced 66.27%	68,575 $1.72 Million
Q1 2021 May 13, 2021	SELL	$11.0 - $28.24 $1.48 Million - $3.81 Million	-134,753 Reduced 66.27%	68,575 $1.72 Million
Q4 2020 Nov 08, 2023	BUY	$10.12 - $13.94 $2.06 Million - $2.83 Million	203,328 New	203,328 $2.44 Million
Q4 2020 Feb 16, 2021	BUY	$10.12 - $13.94 $63,755 - $87,822	6,300 Added 3.2%	203,328 $2.44 Million
Q3 2020 Nov 08, 2023	BUY	$9.93 - $13.47 $445,012 - $603,658	44,815 Added 29.44%	197,028 $1.97 Million
Q3 2020 Nov 13, 2020	BUY	$9.93 - $13.47 $445,012 - $603,658	44,815 Added 29.44%	197,028 $1.97 Million
Q2 2020 Nov 08, 2023	BUY	$9.56 - $12.51 $1.46 Million - $1.9 Million	152,213 New	152,213 $1.59 Million
Q2 2020 Aug 13, 2020	BUY	$9.56 - $12.51 $1.46 Million - $1.9 Million	152,213 New	152,213 $1.59 Million

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $641M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.